These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11004222)

  • 21. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial.
    Abramowicz D; Vanrenterghem Y; Squifflet JP; Kuypers D; Mourad M; Meurisse M; Wissing M
    Clin Transplant; 2005 Aug; 19(4):475-82. PubMed ID: 16008591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.
    Ekberg H; Bernasconi C; Tedesco-Silva H; Vítko S; Hugo C; Demirbas A; Acevedo RR; Grinyó J; Frei U; Vanrenterghem Y; Daloze P; Halloran P
    Am J Transplant; 2009 Aug; 9(8):1876-85. PubMed ID: 19563339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation.
    Sarwal MM; Yorgin PD; Alexander S; Millan MT; Belson A; Belanger N; Granucci L; Major C; Costaglio C; Sanchez J; Orlandi P; Salvatierra O
    Transplantation; 2001 Jul; 72(1):13-21. PubMed ID: 11468528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients.
    Cole E; Landsberg D; Russell D; Zaltzman J; Kiberd B; Caravaggio C; Vasquez AR; Halloran P
    Transplantation; 2001 Sep; 72(5):845-50. PubMed ID: 11571448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft.
    Grinyó JM; Gil-Vernet S; Seron D; Hueso M; Fulladosa X; Cruzado JM; Moreso F; Fernandez A; Torras J; Riera L; Castelao AM; Alsina J
    Nephrol Dial Transplant; 1998 Oct; 13(10):2601-4. PubMed ID: 9794567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective randomized study comparing cyclosporine versus tacrolimus combined with daclizumab, mycophenolate mofetil, and steroids in heart transplantation.
    Sánchez-Lázaro IJ; Almenar L; Martínez-Dolz L; Buendía-Fuentes F; Agüero J; Navarro-Manchón J; Vicente JL; Salvador A
    Clin Transplant; 2011; 25(4):606-13. PubMed ID: 20682020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-2 receptor blockers in liver transplantation: initial experience with daclizumab in Chile.
    Innocenti F; Humeres R; Zamboni M; Sanhueza E; Zapata R; Hepp J; Rius M
    Transplant Proc; 2003 Nov; 35(7):2520-1. PubMed ID: 14612001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Mycophenolate Mofetil Acute Renal Rejection Study Group
    Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alemtuzumab induction in deceased donor kidney transplantation.
    Huang E; Cho YW; Hayashi R; Bunnapradist S
    Transplantation; 2007 Oct; 84(7):821-8. PubMed ID: 17984833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil.
    Wüthrich RP; Weinreich T; Ambühl PM; Schwarzkopf AK; Candinas D; Binswanger U
    Nephrol Dial Transplant; 1999 Feb; 14(2):394-9. PubMed ID: 10069195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
    Ciancio G; Miller A; Burke GW; Gharagozloo H; Rosen A; Roth D; Kupin W; Pinna A; Cespedes M; Esquenazi V; Miller J
    Transplant Proc; 2001; 33(1-2):1013-4. PubMed ID: 11267169
    [No Abstract]   [Full Text] [Related]  

  • 34. Cyclosporine-sparing effects of daclizumab in renal allograft recipients.
    Ingle GR; Moudgil A; Vo A; Jordan SC
    Am J Health Syst Pharm; 2005 Feb; 62(4):391-6. PubMed ID: 15745891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
    Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
    Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.
    Hirose R; Roberts JP; Quan D; Osorio RW; Freise C; Ascher NL; Stock PG
    Transplantation; 2000 Jan; 69(2):307-11. PubMed ID: 10670644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation.
    Joyal D; Cantarovich M; Cecere R; Giannetti N
    Clin Transplant; 2004 Oct; 18(5):493-6. PubMed ID: 15344949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients.
    Bruce DS; Sollinger HW; Humar A; Sutherland DE; Light JA; Kaufman DB; Alloway RR; Lo A; Stratta RJ
    Transplantation; 2001 Nov; 72(10):1637-43. PubMed ID: 11726823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mycophenolate mofetil, with cyclosporine and prednisone, reduces early rejection while allowing the use of less antilymphocytic agent induction and cyclosporine in renal recipients with delayed graft function.
    Arnold AN; Wombolt DG; Whelan TV; Chidester PD; Restaino I; Gelpi B; Stewart M; Hurwitz RL; McCune TR
    Clin Transplant; 2000 Aug; 14(4 Pt 2):421-6. PubMed ID: 10946782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Could prophylactic monoclonal antibody improve kidney graft survival?
    Pourmand G; Saraji A; Salem S; Mehrsai A; Nikoobakht MR; Taherimahmoudi M; Rezaeidanesh M; Asadpour A
    Transplant Proc; 2009 Sep; 41(7):2794-6. PubMed ID: 19765437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.